Literature DB >> 10660150

Autoimmune diseases in families of French patients with multiple sclerosis.

O Heinzlef1, S Alamowitch, V Sazdovitch, P Chillet, A Joutel, E Tournier-Lasserve, E Roullet.   

Abstract

Multiple sclerosis (MS) is associated with autoimmune disorders (AIDs) in individual patients, and limited data suggest a possible familial association of MS and AIDs; however, no systematic study has been conducted on the occurrence of AIDs in the families of MS patients. Using a standardized interview focused on AIDs, we obtained the family histories of 357 consecutive patients from our MS clinic. Adequate information was obtained on 1971 first-degree relatives. Fifty-five patients (15.4%) had first-degree relatives with MS (n=22, 6.2%) another AID (n = 30, 8.4%), or both (n = 3, 0.8%). In 16 families (4.5%), at least 3 first-degree relatives had MS or another AID. MS, Grave's disease, rheumatoid arthritis, vitiligo, type 1 insulin-dependent diabetes mellitus, and uveitis, were the most common AIDs in these families. Such multiplex families (families with MS plus AID) are appropriate for identifying susceptibility genes that may be common to MS and other AIDs.

Entities:  

Mesh:

Year:  2000        PMID: 10660150     DOI: 10.1034/j.1600-0404.2000.101001036.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  13 in total

1.  Relationship between target antigens and major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously.

Authors:  L R Zakka; D B Keskin; P Reche; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

2.  Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy.

Authors:  Alice Laroni; Massimiliano Calabrese; Paola Perini; Maria Paola Albergoni; Federica Ranzato; Michela Tiberio; Leontino Battistin; Paolo Gallo
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 3.  [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

Authors:  C Warnke; B C Kieseier; U Zettl; H-P Hartung
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

4.  Common genetic determinants of uveitis shared with other autoimmune disorders.

Authors:  Mary J Mattapallil; Azize Sahin; Phyllis B Silver; Shu-Hui Sun; Chi-Chao Chan; Elaine F Remmers; J Fielding Hejtmancik; Rachel R Caspi
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

Authors:  Alasdair J Coles; Amanda Cox; Emmanuelle Le Page; Joanne Jones; S Anand Trip; Jackie Deans; Shaun Seaman; David H Miller; Geoff Hale; Herman Waldmann; D Alastair Compston
Journal:  J Neurol       Date:  2005-07-27       Impact factor: 4.849

Review 6.  The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy.

Authors:  Peter O Behan; Abhijit Chaudhuri
Journal:  Inflammopharmacology       Date:  2010-09-24       Impact factor: 5.093

7.  Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort.

Authors:  J S Sloka; Pryse-W E M Phillips; M Stefanelli; C Joyce
Journal:  J Autoimmune Dis       Date:  2005-11-09

Review 8.  How do autoimmune diseases cluster in families? A systematic review and meta-analysis.

Authors:  Jorge Cárdenas-Roldán; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  BMC Med       Date:  2013-03-18       Impact factor: 8.775

9.  Adalimumab in the treatment of arthritis.

Authors:  Philip J Mease
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

10.  Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.

Authors:  Joanne L Jones; Sara A J Thompson; Priscilla Loh; Jessica L Davies; Orla C Tuohy; Allison J Curry; Laura Azzopardi; Grant Hill-Cawthorne; Michael T Fahey; Alastair Compston; Alasdair J Coles
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.